Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Sep. 30, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash Flows From Operating Activities                                                
Net loss $ (10,663) $ (7,446) $ (5,304) $ (3,326) $ (4,299) $ (3,126) $ (2,001) $ (3,277) $ (3,400) $ (6,390) $ 2,330 $ (8,003) $ (2,844) $ (5,296) $ (5,405) $ (7,488) $ (4,614) $ (4,454) $ (26,740) $ (12,703) $ 12,553 $ (22,003) $ (13,623) $ (16,768)
Adjustments to reconcile net loss to net cash used in operating activities:                                                
Depreciation and amortization                                     4,524 3,801        
Interest accretion                                     440 331        
Bad debt expense                                     499        
Reversal of DOJ accrual                                     (350)        
Mark to market on warrants                                     (279) 112        
Stock-based compensation                                     1,535 2,270        
Deferred income taxes                                     18        
Change in estimate on collectability of accounts receivable                                     3,479        
Change in fair value of contingent consideration                                     (44) 1,522        
Other gains and expenses, net                                     18        
Other changes in operating assets and liabilities:                                                
Increase in accounts receivable                                     (1,102) (3,546)        
Decrease (increase) in other current assets                                     129 (501)        
Increase in other long-term assets                                     (11)        
(Decrease) increase in accounts payable                                     (938) 668        
Increase in accrued salaries and bonus                                     362 150        
Decrease in accrued liabilities                                     (1,301) (345)        
Increase (decrease) in long-term liabilities                                     454 (82)        
Net cash used in operating activities                                     (18,957) (8,673)        
Cash Flows From Investing Activity                                                
Acquisition of Biopharma, net of cash acquired                                     (13,829)        
Purchase of property and equipment                                     (131) (449)        
Sale of property and equipment                                     13        
Net cash used in investing activity                                     (13,947) (449)        
Cash Flows From Financing Activities                                                
Issuance of common stock, net of expenses                                     6,478        
Issuance of preferred stock, net of expenses                                     25,744        
Payment of CGIX note and related interest                                     (6,024)        
Borrowings on Line of Credit                                     3,000        
Cash paid for repurchase of restricted shares                                     (41) (9)        
Net cash provided by (used in) financing activities                                     29,157 (9)        
Net decrease in cash and cash equivalents                                     (3,747) (9,131)        
Cash and cash equivalents - beginning of year       $ 6,068       $ 15,199                     6,068 15,199        
Cash and cash equivalents - end of year $ 2,321       $ 6,068                           $ 2,321 $ 6,068 $ 15,199